Company Overview
NeurAxis, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops neuromodulation therapies designed to address chronic and debilitating conditions in both children and adults across the United States. The company's primary product offering is the IB-Stim system, a percutaneous electrical nerve field stimulation technology intended for patients aged 8 years and older, which represents a specialized niche in medical device innovation. In terms of operational scale, NeurAxis, Inc. maintains a market capitalization of $77.19M and employs a workforce of 24 individuals to drive its research and development efforts. The combination of a relatively small market cap and annual revenue of $3.57M indicates that the company is a micro-cap entity with limited financial resources compared to larger pharmaceutical peers, suggesting that its growth trajectory is heavily dependent on the successful commercialization of its specific neuromodulation therapies and the expansion of its patient base within the targeted demographic.
Financial Health
The company reported a total revenue of $3.57M for the trailing twelve months, yet it recorded a net income of $-8,615,152 and an EBITDA of $-7,139,839, highlighting a significant disparity between top-line generation and profitability. This substantial gap between revenue and net income reveals a cost structure characterized by high operating expenses relative to sales, which is typical for early-stage biotechnology firms but necessitates careful management to avoid further erosion of cash reserves. NeurAxis, Inc. generated a free cash flow of $-3,857,785, indicating that the company is currently burning cash to fund its operations and development pipeline, which limits its immediate financial flexibility and reliance on external capital raises or existing cash balances. The margin profile further illustrates these financial pressures, with a gross margin of 84.2% reflecting strong pricing power or low cost of goods sold, contrasted sharply by an operating margin of -177.3% and a profit margin of -218.5% that signify severe underperformance in covering overhead costs and generating net profit. Regarding balance sheet strength, the company holds $4.97M in cash against $426,610 in debt, resulting in a debt-to-equity ratio of 12.55, which suggests a highly leveraged position relative to equity rather than a conservative one due to the negative equity implied by the losses. However, the current ratio stands at 2.05, which indicates that the company maintains sufficient liquid assets to cover its short-term liabilities, providing a buffer against immediate liquidity crises despite the high debt-to-equity leverage. Finally, the return on equity is -285.4% and the return on assets is -80.6%, metrics that reveal that management effectiveness is currently challenged by the inability to generate positive returns on the capital invested in the business, a common challenge for biotech firms in the pre-revenue or low-revenue growth phases.
Valuation Assessment
The valuation metrics for NeurAxis, Inc. present a complex picture due to the lack of traditional profitability measures, with a trailing P/E ratio of N/A and a forward P/E of -345.00. The negative forward P/E and the absence of a trailing P/E imply that the market is pricing the stock based on future expectations of earnings recovery rather than current performance, reflecting the high uncertainty surrounding the trajectory of future earnings. The price-to-book ratio is 21.63, which indicates that the market is valuing the company at a significant premium over its book value, a common phenomenon for biotechnology firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 21.63 and an EV/EBITDA of -10.18 further suggest that the company is being valued on revenue multiples rather than earnings, underscoring the reliance on growth potential rather than current cash generation. In terms of trading range, the 52-week high is $7.97 and the 52-week low is $1.33, meaning the current price sits at a level that reflects significant volatility and deviation from recent historical highs and lows. The beta value of 2.49 indicates that the stock price is highly volatile and expected to move with significantly greater magnitude than the broader market, exposing investors to substantial price swings during periods of market stress or optimism.
Growth & Income
NeurAxis, Inc. demonstrated a revenue growth rate of 27.2% year-over-year, while earnings growth is N/A due to the company's net losses, implying that the top line is expanding faster than the bottom line can recover. As the company is not a dividend payer, it does not distribute a dividend yield or operate with a payout ratio, as indicated by a 0.0% payout ratio and a dividend yield of N/A. This structure implies that the company retains all of its earnings, however negative they may be currently, to reinvest into research, development, and commercialization efforts rather than paying dividends to shareholders. Consequently, the overall growth and income profile is defined by strong revenue expansion coupled with a lack of current profitability and income distribution, requiring the company to secure additional funding to sustain its growth momentum.